LONDON, UK / ACCESSWIRE / January 20, 2020 / As we expected, 2019 was a year of data readouts for epigenetics specialist Oryzon (ORY). The company presented new data from the ongoing Phase IIa clinical trials with both assets at eight conferences last year. All readouts were still interim. This and the fact that Phase IIa trials, in general, are relatively small and focus on safety meant that the share price did not reach new highs despite all readouts being positive. Final results from the trials are expected throughout 2020-21 and Oryzon is already initiating a Phase IIb trial with its CNS asset in borderline personality disorder (BPD). This will provide plenty more catalysts in the coming months. Our valuation is slightly higher at €454m or €9.9/share.
Our valuation of Oryzon is slightly higher at €454m or €9.9 per share, up from €437m or €9.5 per share, mainly due to rolling our model forward. We leave our assumptions unchanged. The main near-term catalysts include vafidemstat Phase IIa REIMAGINE-AD data from AD patients in Q220; vafidemstat Phase IIa ETHERAL EU six-month interim trial results in H120; updated data from iadademstat Phase IIa CLEPSIDRA in SCLC and Phase IIa ALICE in AML some time in 2020.
Click here to view the full report.
Subscribe to Edison's content to receive reports by email.
All reports published by Edison are free-to-access and available on the website.
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Jonas Peciulis, +44 (0)20 3077 5728
healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group-
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
View source version on accesswire.com:
https://www.accesswire.com/573560/Edison-Issues-Outlook-On-Oryzon-Genomics-ORY
